conventional wisdom stated by eminent textbooks is that it is not possible to get chickenpox twice - the argument claims that a single chickenpox infection provides subsequent lifelong immunity
however it is argued (1) that if immunity was lifelong then shingles would not occur since this represents a localised reactivation of the virus (indicating a failure of immunological control of latency)
there is evidence that true re-infection with chickenpox can occur (2)
twenty-three healthy and apparently immunocompetent children with a history of 2-5 episodes of chickenpox were studied after repeat disease
serial sera were tested for VZV-IgG subclass patterns and VZV IgG and G-subclass antibody avidity by urea elution enzyme linked immunoassay (ELISA)
of 11 patients studied within 8 weeks of repeat chickenpox (Early Group), mean antibody avidity was significantly lower (31.3 +/- 26.81) than control (65.1 +/- 12.38) (P < .001). Seven had low avidity antibody (< 30 percent) and an abundance of IgG3 which was a pattern like primary chickenpox, and 2/11 had high avidity antibody characteristic of anamnestic responses. Early Group patients and 12 others studied over 8 weeks after repeat disease (Late Group) showed avidity maturation and attrition of IgG subclass antibodies other than IgG1
at least nine children failed to show VZV-specific secondary (memory) immune responses early in the course of repeat disease. It is possible that failure to maintain or evoke a secondary immune response could explain their susceptibility to repeat chickenpox.
there is also evidence that chickenpox infection has occurred in patients who have been vaccinated and been demonstrated to have antibody and cellular immunity against varicella-zoster virus - in these cases virus typing has demonstrated wild-type virus and not vaccine strain, therefore confirming new infection
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.